Cardiac complications during DLBCL treatment using R-CHOP
OncoReview · 2019
DOI: 10.24292/01.or.119080319 ↗Kurz gefasst
Fachartikel in der Zeitschrift OncoReview, 2019. Verfasst von Barbara Sosnowska-Pasiarska und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.
Zitieren
APA
Sosnowska-Pasiarska, B., Zgódka, P., Steckiewicz, P., & Pasiarski, M. (2019). Cardiac complications during DLBCL treatment using R-CHOP. OncoReview. https://doi.org/10.24292/01.or.119080319
Vancouver
Sosnowska-Pasiarska B, Zgódka P, Steckiewicz P, Pasiarski M. Cardiac complications during DLBCL treatment using R-CHOP. OncoReview. 2019. doi:10.24292/01.or.119080319
BibTeX
@article{SosnowskaPasiarska2019,
author = {Sosnowska-Pasiarska, Barbara and Zgódka, Paweł and Steckiewicz, Paulina and Pasiarski, Marcin},
title = {Cardiac complications during DLBCL treatment using R-CHOP},
journal = {OncoReview},
year = {2019},
doi = {10.24292/01.or.119080319}
}
EUVIMED